FRANKLIN, Mass., Oct. 5 /PRNewswire-FirstCall/ -- Following its recent
merger with Echo Therapeutics, Inc., Sontra Medical Corporation (OTC
Bulletin Board: SONT), a dual platform-enabled transdermal specialty
therapeutics and diagnostics company, today announced that it has changed
its corporate name to Echo Therapeutics, Inc., effective Monday, October 8,
2007. In addition, on October 8, 2007, the Company's OTC Bulletin Board
ticker symbol will change to "ECTE" and its corporate website address will
become http://www.echotx.com.
"Our new name better reflects our expanded strategic focus on building
a broad pipeline of advanced topical formulations of FDA-approved specialty
pharmaceutical products and next generation needle-free transdermal
diagnostics," said Patrick T. Mooney, M.D., CEO of Echo Therapeutics.
About Echo Therapeutics
Echo Therapeutics is a dual platform-enabled, specialty therapeutics
and diagnostics company developing an extensive pipeline of advanced
topical formulations of FDA-approved products and a suite of needle-free
transdermal diagnostics. Echo is developing a next generation, needle-free
Continuous Transdermal Glucose Monitor (CTGM) system for use in the
diabetes home care and hospital critical care markets. Echo's next
generation CTGM system leverages its FDA-approved SonoPrep(R)
ultrasound-mediated skin permeation technology platform. Echo is also
developing a broad portfolio of advanced topical formulations of
well-established, FDA-approved products using its proprietary AzoneTS(TM)
dermal penetration technology. Echo has submitted a New Drug Application
(NDA) to the FDA for the approval of its lead Azone TS- based product,
Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses.
SonoPrep is a registered trademark of Echo Therapeutics, Inc.
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. Any
forward- looking statements contained herein are based on current
expectations, but are subject to a number of risks and uncertainties. The
factors that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to our ability to develop, market and sell
pharmaceutical or diagnostic products based on our AzoneTS and SonoPrep
platform technologies, including AzoneTS-based Durhalieve for
corticosteroid responsive dermatoses and a SonoPrep-based continuous
transdermal glucose monitor system for the diabetes and hospital critical
care markets; the availability of substantial additional equity capital to
support our robust research, development and product commercialization
activities; and the success of our AzoneTS and SonoPrep business, research,
development, and regulatory approval, marketing and distribution plans and
strategies. These and other factors are identified and described in more
detail in our filings with the SEC, including, without limitation, our
respective annual reports on Form 10-KSB for the year ended December 31,
2006, our most recent quarterly reports on Form 10-QSB, and our current
reports on Form 8-K. Echo Therapeutics, Inc. does not undertake to update
these forward-looking statements.
10 Forge Parkway
Franklin, MA 02038, USA
Tel: 1+ 877-4-SONTRA (766878)
Fax: 1+ 508-553-8760
http://www.echotx.com
Investor Relations Contacts:
Patrick T. Mooney, M.D., CEO
508-530-0329
pmooney@echotx.com
SOURCE Echo Therapeutics, Inc.
 back to top
Related links:
http://www.sontra.com
http://www.echotx.com
CONTACT:
Patrick T. Mooney, M.D., CEO of Echo
Therapeutics, Inc., +1-508-530-0329, pmooney@echotx.com
|
